依洛尤单抗在ASCVD患者治疗中的疗效与安全性观察

Observation on the Efficacy and Safety of Ilozumab in the Treatment of ASCVD Patients

探讨ASCVD患者应用依洛尤单抗的疗效与安全性。选择2021年3月—2022年11月于盐城市第一人民医院就诊的114例动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)患者为研究对象,其中对照组54例,试验组60例。对照组接受瑞舒伐他汀治疗,试验组在瑞舒伐他汀治疗基础上加用依洛尤单抗,治疗6个月。结果显示,与对照组相比,试验组在瑞舒伐他汀治疗基础上加用依洛尤单抗治疗后TC、LDL-C、TG和ApoB水平显著降低(P<0.05),斑块面积显著减小(P<0.05)。超高危组和极高危组ASCVD患者接受依洛尤单抗治疗前后TC、LDL-C、TG、HDL、ApoA、ApoB、LP(a)水平变化相似,组间差异均无统计学意义(P>0.05)。6个月后,试验组超高危ASCVD患者LDL-C达标率为63%,而对照组超高危ASCVD患者LDL-C达标率仅为11%(P<0.05)。研究发现,瑞舒伐他汀联合依洛尤单抗治疗ASCVD患者可以更有效地降低患者LDL-C水平,提高LDL-C达标率,缩小颈动脉斑块面积,降低终点事件发生的风险,且安全性良好。

Exploring the efficacy and safety of using ilozumab in ASCVD patients.114 patients with atherosclerotic cardiovascular disease(ASCVD)who were admitted to Yancheng No.1 People’s Hospital from March 2021 to November 2022 were selected as the study subjects,including 54 cases in the control group and 60 cases in the test group.The control group received treatment with rosuvastatin,while the experimental group received treatment with ilozumab in addition to rosuvastatin for 6 months.The results showed that compared with the control group,the experimental group significantly reduced the levels of TC,LDL-C,TG,and ApoB(P<0.05)and plaque area(P<0.05)after receiving treatment with rosuvastatin in addition to ilozumab.The levels of TC,LDL-C,TG,HDL,ApoA,ApoB,and LP(a)in ASCVD patients in the ultra-high risk group and the extremely high-risk group before and after treatment with ilozumab were similar,and there was no statistically significant difference between the groups(P>0.05).After 6 months,the LDL-C compliance rate of the experimental group’s ultra-high risk ASCVD patients was 63%,while the LDL-C compliance rate of the control group’s ultra-high risk ASCVD patients was only 11%(P<0.05).Research has found that the combination of rosuvastatin and ilozumab in the treatment of ASCVD patients can more effectively reduce LDL-C levels,improve LDL-C compliance rates,reduce the area of carotid artery plaques,reduce the risk of endpoint events,and have good safety.